Ann: Presenting at Bell potter healthcare conference, page-20

in regards to NAN - it had already rerated before I knew of it - i use it as a guide of what insto’ s will value medical companies at once they are achieving revenue. cheapo IVF providers are using a ‘wipe system’ - eg they have competition here notwithstanding their patents and imho they will have to majority rely on consumable sales for ongoing revenue. They aren’t going to rerate 5 or 6 times from here - which is what I look for

in regards to XRO - it’s re-rated and it’s psychologically too hard to buy 6x the price sold at - I look for small caps that will rerate